葛兰素史克Glaxosmithkline plc (GSK) 2014年年度报告「LSE」.pdf

1、Annual Report 2014“I am proud to work on our respiratory portfolio and know how important these medicines are to the lives of patients.”Julie,GSK respiratory packaging operator,Ware,UKGSK Annual Report 2014Overview of 2014Performance summary23.0bn2014 Group turnover(down 3%CERa)6.6bnCore operating p

2、rofitb(down 6%CERa)3.6bn2014 Total operating profit(down 40%CER)4.1bnReturned to shareholders via dividends and share buybacks95.4pCore earnings per shareb(down 1%)57.3pTotal earnings per share(down 40%primarily reflecting non-cash adjustments)40Around 40 new molecular entities in phase II and III1.

3、5bnNew product sales(up 84%)1st2014 Access to Medicine Index100%All countries have fully implemented new sales force compensation model1stCompany to file for regulatory approval for malaria vaccine candidate84%Dow Jones Sustainability Index score,putting us in top 2%of the pharmaceutical sector“2014

4、 was a significant year for GSK.It was not without its challenges and this was reflected in our trading performance,although I am pleased with how the Group responded.The standout event of the year was our proposed three-part transaction with Novartis which will accelerate our strategy of making GSK

5、 a simpler,stronger and more balanced platform for long-term growth.”Sir Andrew Witty Chief Executive Officer Read the CEO statement on page 4Julie(pictured)has been with GSK for 32 years and works as a respiratory packaging operator at our manufacturing site in Ware in the UK.Over the years,her rol

6、e has been to help ensure that our life-saving medicines for COPD and asthma from Ventolin to Seretide and most recently our four new medicines administered by the Ellipta inhaler,Relvar/Breo,Anoro,Incruse and Arnuity are always of the highest quality and are available to patients across the world w